Morgan Stanley’s Global Blood Therapeutics, Inc. GBT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-464,630
| Closed | -$31.6M | – | 8178 |
|
|
2022
Q3 | $31.6M | Sell |
464,630
-391,669
| -46% | -$21.6M | ﹤0.01% | 1712 |
|
|
2022
Q2 | $27.4M | Buy |
856,299
+287,760
| +51% | +$8.42M | ﹤0.01% | 1942 |
|
|
2022
Q1 | $19.7M | Buy |
568,539
+367,681
| +183% | +$11M | ﹤0.01% | 2130 |
|
|
2021
Q4 | $5.88M | Sell |
200,858
-110,385
| -35% | -$3.42M | ﹤0.01% | 3548 |
|
|
2021
Q3 | $7.93M | Sell |
311,243
-238,739
| -43% | -$7.02M | ﹤0.01% | 3176 |
|
|
2021
Q2 | $19.3M | Buy |
549,982
+374,402
| +213% | +$14.6M | ﹤0.01% | 2192 |
|
|
2021
Q1 | $7.16M | Sell |
175,580
-97,327
| -36% | -$4.47M | ﹤0.01% | 3028 |
|
|
2020
Q4 | $11.8M | Buy |
272,907
+163,515
| +149% | +$8.06M | ﹤0.01% | 2329 |
|
|
2020
Q3 | $6.03M | Buy |
109,392
+25,373
| +30% | +$1.61M | ﹤0.01% | 2532 |
|
|
2020
Q2 | $5.3M | Sell |
84,019
-317,832
| -79% | -$21.8M | ﹤0.01% | 2599 |
|
|
2020
Q1 | $20.5M | Buy |
401,851
+149,473
| +59% | +$10M | 0.01% | 1256 |
|
|
2019
Q4 | $20.1M | Buy |
252,378
+131,950
| +110% | +$7.82M | ﹤0.01% | 1657 |
|
|
2019
Q3 | $5.84M | Sell |
120,428
-35,644
| -23% | -$1.86M | ﹤0.01% | 2694 |
|
|
2019
Q2 | $8.21M | Sell |
156,072
-5,732
| -4% | -$329K | ﹤0.01% | 2368 |
|
|
2019
Q1 | $8.56M | Sell |
161,804
-89,077
| -36% | -$4.38M | ﹤0.01% | 2180 |
|
|
2018
Q4 | $10.3M | Sell |
250,881
-33,501
| -12% | -$1.26M | ﹤0.01% | 2097 |
|
|
2018
Q3 | $10.8M | Buy |
284,382
+35,878
| +14% | +$1.59M | ﹤0.01% | 2326 |
|
|
2018
Q2 | $11.2M | Sell |
248,504
-126,743
| -34% | -$5.77M | ﹤0.01% | 2240 |
|
|
2018
Q1 | $18.1M | Buy |
375,247
+61,336
| +20% | +$3.42M | 0.01% | 1759 |
|
|
2017
Q4 | $12.4M | Sell |
313,911
-113,577
| -27% | -$4.24M | ﹤0.01% | 2184 |
|
|
2017
Q3 | $13.3M | Sell |
427,488
-80
| -0% | -$2.25K | ﹤0.01% | 1999 |
|
|
2017
Q2 | $11.7M | Buy |
427,568
+92,696
| +28% | +$2.76M | ﹤0.01% | 2028 |
|
|
2017
Q1 | $12.3M | Buy |
334,872
+195,323
| +140% | +$4.92M | ﹤0.01% | 1996 |
|
|
2016
Q4 | $2.02M | Buy |
139,549
+112,159
| +409% | +$1.97M | ﹤0.01% | 3923 |
|
|
2016
Q3 | $631K | Sell |
27,390
-45,482
| -62% | -$867K | ﹤0.01% | 4378 |
|
|
2016
Q2 | $1.21M | Buy |
72,872
+35,593
| +95% | +$718K | ﹤0.01% | 3831 |
|
|
2016
Q1 | $591K | Buy |
37,279
+34,318
| +1,159% | +$610K | ﹤0.01% | 4317 |
|
|
2015
Q4 | $96K | Sell |
2,961
-83,096
| -97% | -$3.6M | ﹤0.01% | 5430 |
|
|
2015
Q3 | $3.63M | Buy |
+86,057
| New | +$4.06M | ﹤0.01% | 2936 |
|
Other funds holding GBT
Morgan Stanley's GBT Position: Q4 2022 in Review
Morgan Stanley sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 464,630 shares — an estimated $31.6M sold.
Morgan Stanley first reported a position in GBT in Q3 2015 and held it in 29 quarters. The position peaked at $31.6M in Q3 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.
- Morgan Stanley reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
- Morgan Stanley sold 464,630 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $31.6M.
- Morgan Stanley first reported a position in Global Blood Therapeutics, Inc. in Q3 2015 and held it in 29 quarters.
- Morgan Stanley's Global Blood Therapeutics, Inc. position peaked at $31.6M in Q3 2022.
- 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.
Based on Morgan Stanley's 13F filing for Q4 2022, filed 14 Feb 2023.